Structure Therapeutics (NASDAQ:GPCR) Coverage Initiated at Stifel Nicolaus

Stifel Nicolaus began coverage on shares of Structure Therapeutics (NASDAQ:GPCR) in a research report report published on Wednesday morning, Marketbeat.com reports. The firm issued a buy rating and a $50.00 price objective on the stock.

Other analysts also recently issued research reports about the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $65.00 price target on shares of Structure Therapeutics in a report on Monday, September 23rd. Morgan Stanley initiated coverage on shares of Structure Therapeutics in a report on Monday, September 23rd. They issued an “overweight” rating and a $118.00 target price on the stock. HC Wainwright reiterated a “buy” rating and set a $80.00 target price on shares of Structure Therapeutics in a research note on Thursday, December 19th. Finally, JMP Securities restated a “market outperform” rating and issued a $91.00 price target on shares of Structure Therapeutics in a research note on Wednesday, December 18th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $81.29.

Structure Therapeutics Price Performance

Shares of NASDAQ:GPCR opened at $27.04 on Wednesday. Structure Therapeutics has a 1 year low of $25.90 and a 1 year high of $62.74. The company has a market cap of $1.55 billion, a P/E ratio of -36.54 and a beta of -2.78. The stock’s fifty day moving average price is $32.63 and its 200-day moving average price is $36.70.

Hedge Funds Weigh In On Structure Therapeutics

A number of hedge funds have recently modified their holdings of the company. Wellington Management Group LLP lifted its position in shares of Structure Therapeutics by 2.9% in the third quarter. Wellington Management Group LLP now owns 7,769,771 shares of the company’s stock valued at $341,015,000 after acquiring an additional 221,851 shares in the last quarter. FMR LLC raised its stake in Structure Therapeutics by 6.7% during the 3rd quarter. FMR LLC now owns 6,128,444 shares of the company’s stock valued at $268,977,000 after purchasing an additional 383,635 shares during the period. Janus Henderson Group PLC boosted its stake in Structure Therapeutics by 18.0% in the 3rd quarter. Janus Henderson Group PLC now owns 3,956,878 shares of the company’s stock worth $173,623,000 after purchasing an additional 602,609 shares during the period. Driehaus Capital Management LLC grew its holdings in Structure Therapeutics by 3.5% during the 2nd quarter. Driehaus Capital Management LLC now owns 2,577,136 shares of the company’s stock valued at $101,204,000 after buying an additional 86,833 shares in the last quarter. Finally, Federated Hermes Inc. raised its position in shares of Structure Therapeutics by 6.6% during the second quarter. Federated Hermes Inc. now owns 2,407,206 shares of the company’s stock valued at $94,531,000 after buying an additional 150,000 shares during the last quarter. 91.78% of the stock is currently owned by institutional investors.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.